Navigation Links
Questcor to Report Second Quarter 2011 Earnings and Conduct Conference Call on July 26, 2011
Date:7/7/2011

ANAHEIM, Calif., July 7, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will release second quarter 2011 financial results  on Tuesday, July 26, 2011 after the close of the U.S. financial markets.  The Company will host a conference call and webcast on Tuesday, July 26, 2011 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the second quarter, as well as current corporate developments.  Conference call details:Date:

Tuesday, July 26, 2011Time:

4:30 p.m. ETDial-in (U.S.):

877-941-8609Dial-in (International):

480-629-9818Web cast:

www.questcor.comTo access an audio replay of the call:Replay (U.S.):

800-406-7325Replay (International):

303-590-3030Replay Passcode:

4455547About QuestcorQuestcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of infantile spasms in children under two years of age and the treatment of nephrotic syndrome. Specifically with respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the possibility of developing markets for other on-label indications and pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  Questcor also markets Doral(R) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Proxy Proposals All Approved at 2011 Shareholder Meeting
2. Questcor Discusses ISS Proxy Recommendations; Provides Business Update
3. Questcor to Report First Quarter 2011 Earnings and Conduct Conference Call on April 26, 2011
4. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011
5. Questcor Pharmaceuticals to Present at the Needham Healthcare Conference
6. Questcor Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference
7. Questcor Pharmaceuticals Selects BDO USA as its Auditor
8. Questcor Reports 2010 Financial Results
9. Questcor to Report Fourth Quarter and Full Year 2010 Earnings and Conduct Conference Call on February 23, 2011
10. Questcor Pharmaceuticals Reports Strong Finish to 2010
11. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... LEXINGTON, Massachusetts , April 27, 2016 ... announces that Jeff Poulton , Chief Financial Officer, will ... in Boston, MA on Wednesday, May ... live audio webcast will be available on the Presentations and ... Subsequently, a replay of the webcast will be available on ...
(Date:4/27/2016)... 2016 At the Sachs CEO ... a Phase 2 clinical study of its lead drug ... cochlear implantation (CI) surgery. This large, placebo-controlled, double-blind, phase ... Germany and France . ... the time of surgery. "Despite advances in cochlear implant ...
(Date:4/26/2016)... 2016 Research and Markets has announced ... Analysis of the Biological Medicine Industry in China 2016" ... analyzes the financial assessment and credit risk of the ... The report provides readers with an in-depth understanding of ... should be aware of. It considers current and future ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... ... Surgery Education and Anzu®, developers of the AnzuMedical™ Knowledge Sharing and Collaboration ... Collaborative Residency Network. The platform is scheduled to launch in July 2016 and ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... has been named a Top Doc in Physical Medicine and Rehabilitation by Philadelphia ... Castle Connolly Medical, Ltd. by randomly surveying physicians and medical leadership across the ...
(Date:4/28/2016)... ... 2016 , ... Starting today, households across the United States ... Prescription Assistance Program. They are customized to reflect the specific health needs of ... ready-to-use, state-themed card and, in the near future, material that highlights savings on ...
(Date:4/28/2016)... ... , ... North Hollywood dentist , Dr. Hamid Reza, now offers emergency ... comes to dental accidents or critical dental problems. These issues can threaten a person's ... knocked-out teeth, chipped teeth, and many other issues can lead to emergency situations, and ...
(Date:4/28/2016)... California (PRWEB) , ... April 28, 2016 , ... For many, a diet is only ... crave it if it does not look good. In addition, an individual cannot deny the ... well. , The team, therefore, has worked to create a product range that could ...
Breaking Medicine News(10 mins):